Screening for toxoplasmosis should be performed during the prenatal period, thereby helping to prevent serious complications for the fetus. Knowing the pregnant woman’s immune status is equally important, as it allows her to be properly informed about the precautions she should take during pregnancy.
The risks of toxoplasmosis during pregnancy are higher in cases where the pregnant woman has never been exposed to the parasite, since if she becomes infected during pregnancy, she may transmit it to the fetus, which can lead to very serious consequences. During the first three months of pregnancy, the risk of the fetus becoming infected is low, but the risk of complications is higher, such as spontaneous abortion, delayed physical and mental development, and cases of blindness and deafness.
The risk to the fetus depends on the mother’s immunity at the time of parasitemia and is related to the gestational age at which the infection occurs: when maternal infection occurs in the third trimester, transmission to the fetus is more common, but the disease in the newborn is generally subclinical. When infection occurs early in pregnancy, transmission to the fetus is less common, but the disease in the newborn is more severe.
Pregnant women who are not immune to toxoplasmosis should take some basic precautions, such as washing vegetables and fruits thoroughly before eating them, cooking meat well, and washing their hands carefully after preparing it; and, when in direct contact with cats, avoiding contact with their feces.
Toxoplasmosis is diagnosed through serological tests, which detect and measure IgM and IgG antibodies produced by the body in response to an infectious agent.
Once the diagnosis is established and treatment initiated, the pregnant woman should be referred for monitoring of fetal involvement. In the treatment of toxoplasmosis during pregnancy, antibiotics are used to reduce the risk of transmitting the virus to the fetus. The antibiotics that may be used are spiramycin in the first trimester of pregnancy or a combination of sulfadiazine and pyrimethamine in the second and third trimesters of pregnancy.
If you have any questions, please contact us.
We'll be happy to help.
CLINICAL PATHOLOGY LABORATORY
